By binding to GLP-1 receptors in the pancreas, brain, and gut, semaglutide: Stimulates insulin release only when blood glucose is elevated, which significantly reduces hypoglycaemia risk compared to older diabetes drugs Suppresses glucagon reducing the livers release of stored glucose into the bloodstream Slows gastric emptying food leaves the stomach more slowly, producing prolonged fullness and reducing overall caloric intake Acts on the brains appetite centres reducing hunger signals and food cravings Mounjaro (Tirzepatide): Dual GLP-1 + GIP Receptor Agonist Tirzepatide activates the same GLP-1 receptor as semaglutide but also activates a second receptor: the glucose-dependent insulinotropic polypeptide (GIP) receptor
Receptor desensitization is less of a concern here than intuition might suggest
Metab Brain Dis 32(4):1073
At $99 after your first month of treatment, this test provides clarity on whether your genetics support continued semaglutide use or suggest an alternative compound
GLP-1R agonists cannot be currently recommended as targeted approaches for MASH but should be administered for their indications (T2D, obesity)
Discontinue use and consult a doctor if adverse reactions occur